{
    "title": "Novo Nordisk's weight-loss drug cuts heart disease risk in study",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-12076735/Drugmakers-bulk-bets-weight-loss-treatments.html",
    "date": "2023-05-12",
    "keywords": [
        "drug",
        "obesity",
        "trial",
        "loss",
        "midstage",
        "treatment",
        "wegovy",
        "weight",
        "company",
        "nordisk",
        "study",
        "benefit",
        "version",
        "semaglutide",
        "injection",
        "pfizer",
        "pill",
        "altimmune",
        "pharma",
        "health",
        "image",
        "market",
        "future",
        "following",
        "list",
        "blockbuster",
        "opportunity",
        "novo",
        "drugmaker",
        "june",
        "body",
        "line",
        "ozempic",
        "product",
        "saxenda",
        "eli",
        "year",
        "mounjaro",
        "tirzepatide",
        "approval",
        "nextgeneration",
        "retatrutide",
        "inc",
        "development",
        "onceaday",
        "liver",
        "safety",
        "latestage",
        "program",
        "danuglipron",
        "yearend",
        "amgen",
        "amg133",
        "dose",
        "march",
        "pemvidutide",
        "average",
        "nausea",
        "vomiting",
        "mild",
        "severity",
        "vk2735",
        "reduction",
        "earlystage",
        "window",
        "boehringer",
        "opko",
        "pegapamodutide",
        "side",
        "mariam",
        "pratik",
        "jain",
        "roy",
        "bengaluru",
        "editing",
        "kalluvila",
        "anil",
        "dsilva"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}